A combined adjuvant approach primes robust germinal center responses and humoral immunity in non-human primates.

Animals Immunity, Humoral Germinal Center Adjuvants, Immunologic / pharmacology Antigens Primates Antibodies, Neutralizing HIV Infections HIV Antibodies env Gene Products, Human Immunodeficiency Virus

Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
04 11 2023
Historique:
received: 21 04 2023
accepted: 25 10 2023
medline: 6 11 2023
pubmed: 5 11 2023
entrez: 5 11 2023
Statut: epublish

Résumé

Adjuvants and antigen delivery kinetics can profoundly influence B cell responses and should be critically considered in rational vaccine design, particularly for difficult neutralizing antibody targets such as human immunodeficiency virus (HIV). Antigen kinetics can change depending on the delivery method. To promote extended immunogen bioavailability and to present antigen in a multivalent form, native-HIV Env trimers are modified with short phosphoserine peptide linkers that promote tight binding to aluminum hydroxide (pSer:alum). Here we explore the use of a combined adjuvant approach that incorporates pSer:alum-mediated antigen delivery with potent adjuvants (SMNP, 3M-052) in an extensive head-to-head comparison study with conventional alum to assess germinal center (GC) and humoral immune responses. Priming with pSer:alum plus SMNP induces additive effects that enhance the magnitude and persistence of GCs, which correlate with better GC-T

Identifiants

DOI: 10.1038/s41467-023-42923-x PMID: 37925510 PMC: PMC10625619
pubmed: 37925510
doi: 10.1038/s41467-023-42923-x
pii: 10.1038/s41467-023-42923-x
pmc: PMC10625619
doi:

Substances chimiques

aluminum sulfate 34S289N54E
Adjuvants, Immunologic 0
Antigens 0
Antibodies, Neutralizing 0
HIV Antibodies 0
env Gene Products, Human Immunodeficiency Virus 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

7107

Subventions

Organisme : NIAID NIH HHS
ID : P01 AI048240
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201700022C
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201000004I
Pays : United States
Organisme : NIH HHS
ID : P51 OD011104
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI144462
Pays : United States

Informations de copyright

© 2023. The Author(s).

Références

Nat Rev Drug Discov. 2021 Jun;20(6):454-475
pubmed: 33824489
Cell Rep. 2022 Mar 8;38(10):110485
pubmed: 35263576
Annu Rev Immunol. 2022 Apr 26;40:413-442
pubmed: 35113731
Science. 2023 Jan 27;379(6630):eabn8934
pubmed: 36701450
Immunity. 2017 Jun 20;46(6):1073-1088.e6
pubmed: 28636956
Nature. 2021 Jun;594(7864):553-559
pubmed: 33971664
Immunol Rev. 2017 Jan;275(1):49-61
pubmed: 28133798
PeerJ. 2016 Oct 18;4:e2584
pubmed: 27781170
Immunity. 2016 Mar 15;44(3):542-552
pubmed: 26948373
Sci Transl Med. 2023 Mar;15(685):eadd6383
pubmed: 36454813
Nature. 2022 Sep;609(7929):998-1004
pubmed: 36131022
Semin Immunol. 2018 Oct;39:14-21
pubmed: 29801750
Nat Med. 2020 Jun;26(6):932-940
pubmed: 32393800
Sci Immunol. 2020 Jun 19;5(48):
pubmed: 32561559
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Immunity. 2020 Sep 15;53(3):548-563.e8
pubmed: 32857950
Antimicrob Agents Chemother. 2002 Jun;46(6):1896-905
pubmed: 12019106
Nat Commun. 2022 Oct 23;13(1):6309
pubmed: 36274085
Annu Rev Immunol. 2023 Apr 26;41:153-179
pubmed: 36696570
J Immunol Methods. 2014 Jul;409:131-46
pubmed: 24291345
PLoS Pathog. 2020 Aug 31;16(8):e1008753
pubmed: 32866207
J Virol. 1998 Apr;72(4):2855-64
pubmed: 9525605
Nat Commun. 2015 Apr 10;6:6565
pubmed: 25858157
Cell. 2021 Jun 24;184(13):3573-3587.e29
pubmed: 34062119
Sci Immunol. 2021 Jul 15;6(61):
pubmed: 34266981
Methods Mol Biol. 2009;485:395-405
pubmed: 19020839
Nat Med. 2020 Mar;26(3):430-440
pubmed: 32066977
Sci Immunol. 2021 Dec 03;6(66):eabf1152
pubmed: 34860581
Annu Rev Immunol. 2016 May 20;34:635-59
pubmed: 27168247
PLoS One. 2017 Oct 24;12(10):e0186998
pubmed: 29065175
J Control Release. 2016 Dec 28;244(Pt A):98-107
pubmed: 27847326
J Immunol. 2016 Aug 1;197(3):994-1002
pubmed: 27335502
Cell Rep. 2019 Nov 12;29(7):1756-1766.e8
pubmed: 31722194
Bioinformatics. 2015 Oct 15;31(20):3356-8
pubmed: 26069265
J Exp Med. 2021 Feb 1;218(2):
pubmed: 33355623
Elife. 2018 Nov 09;7:
pubmed: 30412051
Immunity. 2018 Jan 16;48(1):133-146.e6
pubmed: 29287996
Immunity. 2016 Sep 20;45(3):483-496
pubmed: 27617678
Immunity. 2019 Jan 15;50(1):241-252.e6
pubmed: 30552025
J Virol. 2014 Mar;88(5):2489-507
pubmed: 24352443
J Virol. 2005 Aug;79(16):10108-25
pubmed: 16051804
Clin Vaccine Immunol. 2010 Jul;17(7):1055-65
pubmed: 20463105
Cell Rep. 2016 Nov 22;17(9):2195-2209
pubmed: 27880897
Immunity. 2019 May 21;50(5):1132-1148
pubmed: 31117010
Sci Adv. 2021 Dec 10;7(50):eabj6538
pubmed: 34878851
Immunol Rev. 2020 Jul;296(1):120-131
pubmed: 32483855
Immunity. 2021 Feb 9;54(2):355-366.e4
pubmed: 33484642
Clin Immunol. 2016 Aug;169:16-27
pubmed: 27236001
Immunity. 2018 Aug 21;49(2):288-300.e8
pubmed: 30097292
Cell Rep. 2020 Mar 17;30(11):3755-3765.e7
pubmed: 32187547
J Immunol Methods. 2012 Jan 31;375(1-2):57-67
pubmed: 21968254
Cell. 2019 May 16;177(5):1153-1171.e28
pubmed: 31080066

Auteurs

Ivy Phung (I)

Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, 92037, USA.
Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA.
Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA, 92037, USA.
ORCID: 0000-0001-7283-4766

Kristen A Rodrigues (KA)

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, 02139, USA.
ORCID: 0000-0002-0680-9834

Ester Marina-Zárate (E)

Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, 92037, USA.
Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA.
ORCID: 0000-0003-1586-404X

Laura Maiorino (L)

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, 02139, USA.

Bapi Pahar (B)

Tulane National Primate Research Center, Tulane School of Medicine, Covington, LA, 70433, USA.
ORCID: 0000-0003-1949-973X

Wen-Hsin Lee (WH)

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA.
ORCID: 0000-0001-9445-6671

Mariane Melo (M)

Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA.
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, 02139, USA.

Amitinder Kaur (A)

Tulane National Primate Research Center, Tulane School of Medicine, Covington, LA, 70433, USA.

Carolina Allers (C)

Tulane National Primate Research Center, Tulane School of Medicine, Covington, LA, 70433, USA.

Marissa Fahlberg (M)

Tulane National Primate Research Center, Tulane School of Medicine, Covington, LA, 70433, USA.

Brooke F Grasperge (BF)

Tulane National Primate Research Center, Tulane School of Medicine, Covington, LA, 70433, USA.

Jason P Dufour (JP)

Tulane National Primate Research Center, Tulane School of Medicine, Covington, LA, 70433, USA.

Faith Schiro (F)

Tulane National Primate Research Center, Tulane School of Medicine, Covington, LA, 70433, USA.

Pyone P Aye (PP)

Tulane National Primate Research Center, Tulane School of Medicine, Covington, LA, 70433, USA.
ORCID: 0000-0002-4764-3965

Paul G Lopez (PG)

Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, 92037, USA.

Jonathan L Torres (JL)

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA.
ORCID: 0000-0003-0137-8497

Gabriel Ozorowski (G)

Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA.
Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, 92037, USA.
ORCID: 0000-0002-9695-8138

Saman Eskandarzadeh (S)

Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, 92037, USA.

Michael Kubitz (M)

Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, 92037, USA.

Erik Georgeson (E)

Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, 92037, USA.
ORCID: 0000-0001-5137-4625

Bettina Groschel (B)

Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, 92037, USA.

Rebecca Nedellec (R)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, 92037, USA.

Michael Bick (M)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, 92037, USA.

Katarzyna Kaczmarek Michaels (K)

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, 02139, USA.

Hongmei Gao (H)

Department of Surgery, Laboratory for AIDS Vaccine Research & Development, Duke University Medical Center, Duke University, Durham, NC, 27710, USA.
ORCID: 0000-0002-2468-8589

Xiaoying Shen (X)

Department of Surgery, Laboratory for AIDS Vaccine Research & Development, Duke University Medical Center, Duke University, Durham, NC, 27710, USA.
ORCID: 0000-0002-8387-3952

Diane G Carnathan (DG)

Emory National Primate Research Center and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, 30322, USA.

Guido Silvestri (G)

Emory National Primate Research Center and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, 30322, USA.
ORCID: 0000-0001-6602-2470

David C Montefiori (DC)

Department of Surgery, Laboratory for AIDS Vaccine Research & Development, Duke University Medical Center, Duke University, Durham, NC, 27710, USA.
ORCID: 0000-0003-0856-6319

Andrew B Ward (AB)

Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA.
Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA.
ORCID: 0000-0001-7153-3769

Lars Hangartner (L)

Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA.
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, 92037, USA.
ORCID: 0000-0002-3165-2058

Ronald S Veazey (RS)

Tulane National Primate Research Center, Tulane School of Medicine, Covington, LA, 70433, USA.
ORCID: 0000-0002-6298-2391

Dennis R Burton (DR)

Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA.
Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, 02139, USA.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, 92037, USA.
ORCID: 0000-0001-6711-9864

William R Schief (WR)

Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA.
Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, 02139, USA.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, 92037, USA.
ORCID: 0000-0002-1120-0150

Darrell J Irvine (DJ)

Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA. djirvine@mit.edu.
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA. djirvine@mit.edu.
Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, 02139, USA. djirvine@mit.edu.
Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA. djirvine@mit.edu.
Department of Materials Science and Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA. djirvine@mit.edu.
Howard Hughes Medical Institute, Chevy Chase, MD, 20815, USA. djirvine@mit.edu.
ORCID: 0000-0002-8637-1405

Shane Crotty (S)

Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, 92037, USA. shane@lji.org.
Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA. shane@lji.org.
Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA, 92037, USA. shane@lji.org.
ORCID: 0000-0002-6484-6262

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › A combined adjuvant approach primes robust...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Immunité acquise › Immunité humorale › A combined adjuvant approach primes robust...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Système lymphatique › Tissu lymphoïde › Noeuds lymphatiques › Centre germinatif › A combined adjuvant approach primes robust...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Facteurs immunologiques › Adjuvants immunologiques › A combined adjuvant approach primes robust...
questionsmedicales.fr › Facteurs biologiques › Antigènes › A combined adjuvant approach primes robust...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › A combined adjuvant approach primes robust...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps neutralisants › A combined adjuvant approach primes robust...
questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à VIH › A combined adjuvant approach primes robust...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps antiviraux › Anticorps antideltarétrovirus › Anticorps anti-VIH › A combined adjuvant approach primes robust...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines virales › Protéines virales structurales › Protéines de l'enveloppe virale › Produits du gène env › Produits du gène env du virus de l'immunodéficience humaine › A combined adjuvant approach primes robust...